Literature DB >> 33777148

Inhibition of Allogeneic and Autologous T Cell Proliferation by Adipose-Derived Mesenchymal Stem Cells of Ankylosing Spondylitis Patients.

Ewa Kuca-Warnawin1, Magdalena Plebańczyk1, Krzysztof Bonek2, Ewa Kontny1.   

Abstract

BACKGROUND: In ankylosing spondylitis (AS), accompanied by chronic inflammation, T cell expansion plays a pathogenic role; the immunoregulatory properties of bone marrow-derived mesenchymal stem cells (BM-MSCs) are impaired, while functional characteristics of their adipose tissue-derived counterparts are (ASCs) unknown.
METHODS: We evaluated the antiproliferative activity of AS/ASCs, obtained from 20 patients, towards allogeneic and autologous T lymphocytes, using ASCs from healthy donors (HD/ASCs) as the reference cell lines. The PHA-activated peripheral blood mononuclear cells (PBMCs) were cocultured in cell-cell contact and transwell conditions with untreated or TNF + IFNγ- (TI-) licensed ASCs, then analyzed by flow cytometry to identify proliferating and nonproliferating CD4+ and CD8+ T cells. The concentrations of kynurenines, prostaglandin E2 (PGE2), and IL-10 were measured in culture supernatants.
RESULTS: In an allogeneic system, HD/ASCs and AS/ASCs similarly decreased the proliferation of CD4+ and CD8+ T cells and acted mainly via soluble factors. The concentrations of kynurenines and PGE2 inversely correlated with T cell proliferation, and selective inhibitors of these factors synthesis significantly restored T cell response. AS/ASCs exerted a similar antiproliferative impact also on autologous T cells.
CONCLUSION: We report for the first time that despite chronic in vivo exposure to inflammatory conditions, AS/ASCs retain the normal capability to restrain expansion of allogeneic and autologous CD4+ and CD8+ T cells, act primarily via kynurenines and PGE2, and thus may have potential therapeutic value. Some distinctions between the antiproliferative effects of AS/ASCs and HD/ASCs suggest in vivo licensing of AS/ASCs.
Copyright © 2021 Ewa Kuca-Warnawin et al.

Entities:  

Year:  2021        PMID: 33777148      PMCID: PMC7979299          DOI: 10.1155/2021/6637328

Source DB:  PubMed          Journal:  Stem Cells Int            Impact factor:   5.443


  62 in total

1.  Elevated number of recently activated T cells in bone marrow of patients with rheumatoid arthritis: a role for interleukin 15?

Authors:  Ewa Kuca-Warnawin; Tomasz Burakowski; Weronika Kurowska; Monika Prochorec-Sobieszek; Anna Radzikowska; Magdalena Chorazy-Massalska; Pawel Maldyk; Ewa Kontny; Wlodzimierz Maslinski
Journal:  Ann Rheum Dis       Date:  2010-10-26       Impact factor: 19.103

2.  Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells.

Authors:  Rosa Yañez; Alberto Oviedo; Montserrat Aldea; Juan A Bueren; María L Lamana
Journal:  Exp Cell Res       Date:  2010-09-08       Impact factor: 3.905

3.  Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2.

Authors:  Grazia Maria Spaggiari; Andrea Capobianco; Heba Abdelrazik; Flavio Becchetti; Maria Cristina Mingari; Lorenzo Moretta
Journal:  Blood       Date:  2007-10-19       Impact factor: 22.113

4.  CD8+ T cells oligoclonally expanded in synovial fluid at onset of spondyloarthropathy selectively proliferate in response to self-antigens: characterization of cell specificities in nonclonal populations.

Authors:  Miguel A Treviño; Emma Teixeiro; Rafael Bragado
Journal:  J Rheumatol       Date:  2004-10       Impact factor: 4.666

5.  Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis.

Authors:  Paul Bowness; Anna Ridley; Jacqueline Shaw; Antoni T Chan; Isabel Wong-Baeza; Myles Fleming; Fraser Cummings; Andrew McMichael; Simon Kollnberger
Journal:  J Immunol       Date:  2011-01-19       Impact factor: 5.422

Review 6.  Mesenchymal stem cell effects on T-cell effector pathways.

Authors:  Michelle M Duffy; Thomas Ritter; Rhodri Ceredig; Matthew D Griffin
Journal:  Stem Cell Res Ther       Date:  2011-08-11       Impact factor: 6.832

7.  Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1.

Authors:  Adrian Cortes; Sara L Pulit; Paul J Leo; Jenny J Pointon; Philip C Robinson; Michael H Weisman; Michael Ward; Lianne S Gensler; Xiaodong Zhou; Henri-Jean Garchon; Gilles Chiocchia; Johannes Nossent; Benedicte A Lie; Øystein Førre; Jaakko Tuomilehto; Kari Laiho; Linda A Bradbury; Dirk Elewaut; Ruben Burgos-Vargas; Simon Stebbings; Louise Appleton; Claire Farrah; Jonathan Lau; Nigil Haroon; Juan Mulero; Francisco J Blanco; Miguel A Gonzalez-Gay; C Lopez-Larrea; Paul Bowness; Karl Gaffney; Hill Gaston; Dafna D Gladman; Proton Rahman; Walter P Maksymowych; J Bart A Crusius; Irene E van der Horst-Bruinsma; Raphael Valle-Oñate; Consuelo Romero-Sánchez; Inger Myrnes Hansen; Fernando M Pimentel-Santos; Robert D Inman; Javier Martin; Maxime Breban; Bryan Paul Wordsworth; John D Reveille; David M Evans; Paul I W de Bakker; Matthew A Brown
Journal:  Nat Commun       Date:  2015-05-21       Impact factor: 14.919

Review 8.  Prostaglandin E2 As a Modulator of Viral Infections.

Authors:  Willem J Sander; Hester G O'Neill; Carolina H Pohl
Journal:  Front Physiol       Date:  2017-02-14       Impact factor: 4.566

9.  Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species.

Authors:  J Su; X Chen; Y Huang; W Li; J Li; K Cao; G Cao; L Zhang; F Li; A I Roberts; H Kang; P Yu; G Ren; W Ji; Y Wang; Y Shi
Journal:  Cell Death Differ       Date:  2013-10-25       Impact factor: 15.828

Review 10.  Functional enhancement strategies for immunomodulation of mesenchymal stem cells and their therapeutic application.

Authors:  Byung-Chul Lee; Kyung-Sun Kang
Journal:  Stem Cell Res Ther       Date:  2020-09-14       Impact factor: 6.832

View more
  3 in total

Review 1.  Mesenchymal Stem Cells and Their Small Extracellular Vesicles as Crucial Immunological Efficacy for Hepatic Diseases.

Authors:  Yuting Tang; Peipei Wu; Linli Li; Wenrong Xu; Jiajia Jiang
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

2.  Impact and Possible Mechanism(s) of Adipose Tissue-Derived Mesenchymal Stem Cells on T-Cell Proliferation in Patients With Rheumatic Disease.

Authors:  Ewa Kuca-Warnawin; Marzena Olesińska; Piotr Szczȩsny; Ewa Kontny
Journal:  Front Physiol       Date:  2022-01-13       Impact factor: 4.566

3.  Osteogenic differentiation of mesenchymal stem cells promotes c-Jun-dependent secretion of interleukin 8 and mediates the migration and differentiation of CD4+ T cells.

Authors:  Feng Ye; Jinteng Li; Peitao Xu; Zhongyu Xie; Guan Zheng; Wenjie Liu; Guiwen Ye; Wenhui Yu; Jiajie Lin; Zepeng Su; Yunshu Che; Zhaoqiang Zhang; Peng Wang; Yanfeng Wu; Huiyong Shen
Journal:  Stem Cell Res Ther       Date:  2022-02-05       Impact factor: 6.832

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.